← Medical · Causes of death · how systems treat it
Infectious · Master rank #25 · ~1.1% of deaths (Top 20 avg)
Short comparison of all 20 systems on one page. Click a country for the full treatment / prevention / lifestyle page.
High visit frequency, low unit prices, specialist access without US-style referral walls. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Statutory insurance, fee schedule.
Public clusters for most serious care; private ISP for those who pay up. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via S+3Ms (subsidy + MediSave + MediShield + MediFund).
High spend, high access, canton variation. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Mandatory private insurance.
GP gatekeeping; north/south performance gaps. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via SSN tax-funded.
Insurer-organized pathways; low uninsured rate. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Mandatory private insurance, regulated.
GP gatekeeping, NICE pathways, waiting-list rationing for elective care. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via NHS tax-funded.
Very high utilization; hospital-heavy; aggressive screening culture. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via NHI single payer + private hospitals.
Primary-care centered; strong public health infrastructure. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Decentralized tax-funded.
Wealthy Nordic model; GP lists + municipal prevention. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Tax-funded national system.
Ambulatory specialist access; strong pharma/device availability. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Statutory health insurance.
High ambulatory volume; global budgets constrain growth. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via NHI single payer.
Municipal prevention + regional hospitals. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Tax-funded.
Strong primary care; Mediterranean public-health framing. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via SNS tax-funded.
Ambulatory specialists + hospital sector; dense capacity. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Statutory sickness funds.
Fund-integrated care; strong tech/trauma capacity. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Mandatory health funds.
Strong primary care gatekeeping with private hospital overflow. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Universal Medicare + private optional.
Pharmac constrains drug spend; public hospitals for major care. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Tax-funded + private optional.
Single-payer core with wait times; limited private parallel. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Single payer (provincial).
Public primary care + occupational health overlay. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Tax-funded / reforming.
High-tech acute care; prior auth; huge price variation by payer. Vaccination + antivirals for high-risk; hospital surge plans residual. Infectious pathway via Medicare/Medicaid + commercial.